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Background: Estrogen receptor (ER) positive breast cancer can often be treated by hormone therapy; however a
certain population of ER-positive patients become resistant to hormone therapy after long-term hormone treatment.
Ethinylestradiol (EE2) is a derivative of estrogen, which has shown promising effects in these patients.
Methods: We successfully obtained tissue samples from 6 patients undergoing EE2 treatment and examined 13
well-known breast cancer-related factors by immunohistochemistry. Of the 6 patients, 5 responded but one
patient did not.
Results: Before EE2 treatment, staining for both ER and androgen receptor (AR) was strong in the nucleus, and the
progesterone receptor (PgR) was almost no staining. EE2 treatment significantly down-regulated ER and up-regulated
PgR while nuclear and cytosolic AR were oppositely down- and up-regulated, respectively. Cytosolic staining of BRCA1
was significantly up-regulated by EE2 whereas nuclear staining tended to decrease. Individual comparisons suggested
less induction of PgR and decreasing AKT but increasing pAKT in the non-responder following EE2 treatment.
Conclusions: Our observations revealed that EE2 activated ER downstream genes; however it did not stimulate cell
growth. This suggests that hormone resistant cells might receive growth signals from a non-genomic pathway and this
may be reflected in their sensitivity to EE2 treatment.
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resistanceBackground
Estrogen receptor (ER) positive breast cancer is consid-
ered to be a low risk form of the disease and anti-
estrogen treatment is generally applied even though this
disease can be recurrent, if not life-threatening (NCCN
guidelines® http://www.nccn.org/).
There are several different types of anti-estrogenic
agents; Tamoxifen is an antagonist of ER, and has been
widely used to treat cancer in both pre- and post-
menopausal women. Aromatase inhibitors (AIs) are the
representative anti-estrogenic agents in post-menopausal
women, and are the first choice for patients after* Correspondence: hiwase@kumamoto-u.ac.jp
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in any medium, provided the original work is pmenopause. There are several different AI agents available;
the non-steroidal AIs: anastrozole and letorozole, and
the steroidal AI: exemestane. Fulvestrant is an estrogen
receptor antagonist with no agonist effects, which works
by down-regulating the estrogen receptor (Kansra et al.
2005). These agents generally inhibit ER function by either
decreasing production of estrogen or by blocking the
ER itself.
Ethinyl estradiol (EE2) is a derivative of 17β-estradiol
(E2), which is the major endogenous estrogen in humans,
and exhibits estrogenic activity. EE2 is used in many for-
mulations of combined oral contraceptive pills (Hatcher
RA 2004). In addition it has also been prescribed for
patients with prostate cancer for many years, because
administration of EE2 causes a reduction of androgen pro-
duction (Dorner et al. 1985).an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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to be effective against the recurrence of ER positive
breast cancer after long-term anti-estrogen treatment
(Iwase et al. 2013; Ellis et al. 2009). It was believed that
estrogen stimulates the growth and development of
ER-positive breast cancer, so this finding is quite the
opposite to our consensus and the effects are some-
thing of a paradox.
To investigate this effect in more detail, we set up a
clinical trial to evaluate EE2 treatment in our depart-
ment. We registered 18 patients who were prescribed
EE2 treatment after long-term AI treatment, and so far
successfully obtained 23 tissue samples from 6 patients.
Using immunohistochemistry, we analyzed the expres-
sion of known breast cancer-related genes in this study
and examined the effects of EE2.
Results
ER, progesterone receptor (PgR) and Ki67 staining were
observed only in the nucleus, while human EGFR-
related 2 (Her2), Fas, transforming growth factor beta
receptor 1 (TGFβR1) and insulin-like growth factor I re-
ceptor beta (IGF1Rb) were found on the cell membrane
and phosphoinositide 3-kinase (PI3K) was localized in
the cytosol. Androgen receptor (AR), breast cancer
susceptibility gene I (BRCA1), protein kinase B (AKT)
and phosphorylated AKT (pAKT) staining were obser-
ved in both the nucleus and the cytosol. Representative
ER, PgR and AR staining are shown in Figure 1. Nuclear




Figure 1 Representative staining of ER, PgR and AR in patients pre, dur
to EE2. Before EE2 treatment, ER staining was high, PgR staining was low and
EE2, ER decreased, PgR was increased and AR in the nucleus reduced while c
to EE2. Before EE2 treatment, high ER, low PgR and high nuclear AR were obs
However, PgR was not induced and nuclear AR was decreased and not translby histo-score (HS) and cell membrane staining was
categorized into 4 groups as described in Materials
and methods. Results from all 18 samples are shown
in Table 1.
Comparison of staining between groups at different
time-points during EE2 treatment
Statistical comparisons were performed in two ways;
one was to compare between Pre EE2 and (During+Post)
EE2 treatment (Table 2A), the other comparison was
between all 3 groups, Pre, During and Post EE2 treat-
ment (Table 2B). In both comparisons, the expression
of 4 genes appeared to be regulated by EE2 treat-
ment. ER staining was quite strong before EE2 treat-
ment; however it was significantly down-regulated by
EE2 treatment. In contrast virtually no PgR staining
was detectable before EE2 treatment, but it was sig-
nificantly up-regulated after treatment. Before EE2
treatment, strong AR staining could be observed but
was almost completely restricted to the nucleus; how-
ever nuclear AR staining was decreased and cytosolic
AR was increased by EE2. BRCA1 staining was obser-
ved only in the nucleus before and during EE2 treat-
ment, however EE2 significantly increased cytosolic
staining of BRCA1 while nuclear staining tended to de-
crease. Staining of other proteins was not changed by
EE2 treatment.
When expression of membrane proteins; Her2, Fas,
TGFβR1 and IGF1Rb were analyzed, no differences were




ing and post EE2 treatment. A: Staining in patient 4, who responded
AR staining was only observed in the nucleus. After administration of
ytosolic staining increased. B: Staining in patient 3, who did not respond
erved, while after EE2, ER was dramatically decreased as in patient 4.
ocated to the cytosol.
Table 1 Staining results of each samples
ER PgR Ki67 BRCA1 AR IGF1Rb P13K AKT pAKT TUNEL HER2 Fas TGFßR1 GF1Rb
Patient nuc nuc nuc nuc cyto nuc cyto cyto nuc cyto nuc cyto nuc cyto m m m m m
1 pre 158 8 10 121 0 94 0 80 0 46 18 95 5 90 25 1 0 0 3
post 120 10 10 106 95 5 60 70 0 56 0 90 5 0 0 1 10 1 1
2 pre 156 0 20 97 0 124 50 80 0 106 10 42 0 0 0 1 0 2 1
post 110 137 40 4 0 3 0 0 0 109 46 85 0 0 9 1 0 1 3
3 pre 140 6 20 55 0 111 0 90 0 100 105 0 0 40 6 1 0 1 3
post 0 30 50 39 0 5 0 100 0 100 31 0 133 90 6 3 0 1 1
4 pre 156 17 10 116 0 106 0 0 0 88 40 90 0 0 0 1 0 0 1
during 11 203 20 122 0 18 95 0 0 100 85 100 0 0 0 1 0 0 2
post 10 122 30 100 100 15 98 0 0 100 95 95 0 0 3 0 0 1 2
5 pre 172 0 5 100 0 128 0 0 0 15 0 95 16 90 2 2 0 2 1
pre 198 0 3 100 0 109 0 70 0 100 10 80 5 0 0 1 0 1 1
pre 117 0 20 101 0 88 0 0 0 100 90 90 0 24 9 1 0 1 1
pre 162 0 15 98 0 112 0 85 0 100 70 90 0 0 3 1 0 1 1
pre 203 0 10 98 0 120 0 20 0 80 50 80 0 15 0 1 1 1
during 89 141 5 45 0 101 100 90 0 95 19 60 0 0 0 2 0 1 1
post 103 0 20 98 98 100 98 0 0 100 19 95 0 95 0 2 0 1 1
6 pre 205 161 10 80 0 200 90 100 0 98 50 90 46 0 6 1 0 1 3
during 104 170 5 5 0 107 99 0 0 100 3 90 0 0 6 1 0 1 1
Nuclear and cytosolic staining were evaluated by HistoScore. Membrance staining was clasiffied as 0, 1+, 2+ and 3+ following the recommendations for Her2 staining.
nuc: nuclear, cyto: cytosol, m: membrane.
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time-points during EE2 treatment
The therapeutic effect and duration of EE2 treatment
were: patient 1: responder 14 m, patient 2: responder 14
m, patient 3: non-responder 4 m, patient 4: responderTable 2 Statistical evaluation of nuclear and cytosol staining
A Pre EE2 (n=10)
mean (S.E.)
During + Post EE2
(n=8) mean (S.E.)
P-value B
ER nuc 166.7 (9.0) 68.3 (18.2) 0.0006** ER
PgR nuc 19.2 (15.8) 113.1 (24.1) 0.01* PgR
Ki67 nuc 12.3 (1.96) 22.5 (5.82) 0.2 Ki67
BRCA1 nuc 96.6 (5.79) 64.8 (16.7) 0.3 BRCA1
cyto 0 (0) 36.6 (17.8) 0,047*
AR nuc 119.2 (9.79) 44.2 (17.2) 0.039* AR
cyto 14.0 (9.79) 68.75 (15.7) 0.0097**
PI3K cyto 83.3 (9.39) 95.0 (5.73) 0.31 PI3K
AKT nuc 44.3 (11.3) 37.2 (12.6) 0.72 AKT
cyto 75.2 (9.69) 76.8 (11.8) 0.58
pAKT nuc 7.2 (4.5) 17.2 (16.5) 0.63 pAKT
cyto 25.9 (11.4) 23.1 (15.1) 0.57
IGT1Rb cyto 52.5 (13.3) 32.5 (16.1) 0.37 IGT1Rb
TUNEL 5.1 (2.42) 3.0 (1.26) 0.74 TUNEL
The Wilcoxon test/the Kruskal-Wallis test was used to analyze the significance of dif
nuc: nuclear, cyto: cytosol.
*<0.05, **<0.01.12 m, patient 5: responder 8 m, and patient 6: responder
still receiving ongoing treatment for more than 14 m.
To investigate differences in the regulation of selected
genes underlying the different therapeutic effects, we








nuc 166.7 (9.0) 68.0 (28.8) 68.6 (26.1) 0.0024**
nuc 19.2 (15.8) 171.3 (17.9) 78.2 (26.8) 0.0113*
nuc 12.3 (1.96) 10.0 (5.0) 30.0 (7.07) 0.052
nuc 96.6 (5.79) 57.3 (34.3) 69.4 (20.3) 0.56
cyto 0 (0) 0 (0) 58.6 (23.9) 0.0126*
nuc 119.2 (.979) 75.3 (28.7) 25.6 (18.7) 0.0065**
cyto 14.0 (9.79) 98.0 (1.52) 51.2 (22.0) 0.0092**
cyto 83.3 (9.3) 98.3 (1.66) 93.0 (9.41) 0.53
nuc 44.3 (11.3) 35.6 (25.0) 38.2 (16.0) 0.9
cyto 75.2 (9.69) 83.3 (12.0) 73.0 (18.3) 0.81
nuc 7.2 (4.5) 0 (0) 27.6 (26.3) 0.44
cyto 25.9 (11.4) 0 (0) 37.0 (22.6) 0.36
cyto 52.5 (13.3) 30.0 (30.0) 34.0 (21.4) 0.64
5.1 (2.44) 2.0 (2.0) 3.6 (1.74) 0.75
ferences between groups.
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brane staining. Results are shown in Figure 2. This study
was not evaluated statistically because there was only
one patient who did not respond to EE2, however, this
patient appeared to show a different pattern of PgR ex-
pression to the responders, with no increase after EE2
treatment even though ER expression was drastically
reduced, AKT expression seemed to decrease whereas
pAKT expression increased after treatment both in the
nucleus and the cytosol but especially in the nucleus.
Discussion
Hormone therapy is important in breast cancer treatment
and around 70% of patients are categorized as suitable for
hormone therapy (American Cancer Society 2013 http://
www.cancer.org/cancer/breastcancer/detailedguide/breast-
cancer-treating-hormone-therapy). Hormone treatment
can be administered orally or by one shot injection, which
has less influence on bodily functions so that patients can
continue daily life as they are used to (Iwase 2008). There
are a variety of different medicines currently available, in-
cluding anastrozole, letrozole and exemestane as AIs; tam-
oxifen and raloxifene as estrogen receptor modulators;
and fulvestrant as an ER downregulator. Consequently,
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Figure 2 Comparison of expression between Pre and (During+Post) EE2
EE2 treatment whereas patient 3 did not. The average HS was calculated for athey can be switched to another medicine with a different
structure or method of action and if that also fails, they
can again be switched to another medication. Hormone
therapy allows patients to maintain a better quality of life
for a certain duration before chemotherapy is applied
(Carlson et al. 2012).
In breast cancer samples, ER and PgR expression sta-
tus are evaluated by immunohistochemistry. If a sample
shows more than 1% staining for one of these receptors,
it is classified as hormone receptor-positive and hor-
mone treatment is applicable (Hammond et al. 2010).
Comprehensive gene analysis has allowed breast cancers
to be categorized according to their intrinsic subtype
and Luminal A, a group with high expression of the ER,
is considered to be highly responsive to hormone ther-
apy (Sorlie et al. 2001). Therefore, ER and PgR status are
very important for the application of hormone therapy,
especially ER status. However, approximately 30% of ER-
positive cases do not respond favorably to hormone
therapy (Rubens and Hayward 1980) and in addition a
subset of the population may become resistant after
long-term hormone treatment even though they remain
ER positive (Jordan and Ford 2011).
Recently, it was reported that EE2 administration was
































treatment in individual patients. Patients 1,2,4,5 and 6 responded to
patient if they had several samples in a group.
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EE2 is a derivative of estrogen, therefore this treatment
sounds in opposition to endocrine therapy, which is
considered to act by blocking estrogen function. This
paradoxical therapy can postpone the necessity for ad-
ministration of chemotherapy because after EE2 treat-
ment, normal anti-estrogenic agents become effective
again even if treatment with the same medication failed
before.
The very best point to start EE2 treatment is not yet
understood. In a trial of EE2 by Ellis et al., eligible pa-
tients were those with metastatic breast cancer treated
with AIs at least 24 weeks progression-free survival, or
relapse after two or more years of adjuvant AIs (Ellis
et al. 2009). In our study, our inclusion criteria were:
postmenopausal women with breast cancer (not less
than 50 years old) who had progressive disease, and who
were receiving sequential treatments with AIs or Selective
estrogen receptor modulators (SERMs) (the university
hospital medical information network (UMIN) Clinical
Trials Registry (UMIN000002831) http://www.umin.ac.jp/
ctr/index.htm). It would be a great benefit for ER-positive
patients if we could distinguish between hormone therapy
insensitivity and EE2 sensitivity. So far 18 patients have
been registered for EE2 treatment in our department after
long-term Als treatment, and have shown very interesting
results; the response rate was 50% and the clinical benefit
was 56% (Iwase et al. 2013). Furthermore, we successfully
obtained 23 tissue samples from 6 patients. Therefore, first
of all, we focused on 13 genes and factors, which are
related to cancer progression and performed immuno-
staining to see how these genes were regulated during EE2
treatment in this study.
The genes which we selected could be divided into 4
categories, hormone-related factors: ER, PgR and AR;
growth/proliferative factors: Her2, IGF1Rb, TGFβR1 and
Ki67; intracellular signaling factors: AKT, pAKT and PI3K;
and apoptosis-related factors: BRCA1, Fas and TUNEL.
Before EE2, i.e. under estrogen-depleted conditions,
ER and AR staining was quite strong while virtually no
PgR staining was observed, as we had expected. In a
comparison among samples of pre-, during and post-
treatment or between pre- and (during+post)-treatment,
only ER, PgR, AR and BRCA1 showed any significant
difference between the treatment groups. Comparison
among pre-, during- and post-treatment or between pre-
and (during+post)-treatment showed that ER was signifi-
cantly down-regulated by EE2 treatment whereas PgR
was up-regulated (Table 2A,B). Nuclear AR staining was
down-regulated whereas cytosolic AR was up-regulated
by EE2. ER, PgR and AR are members of the nuclear
receptor superfamily and are closely related to estrogen.
PgR is well-known as a down-stream gene of ER (Lin
et al. 2004) therefore this result strongly suggests thatEE2 activates ER signaling. AR has a strong relationship
with ER either directly (Panet-Raymond et al. 2000;
Peters et al. 2009) or by regulation of their ligands.
Transportation and translocation of the AR to the nu-
cleus is performed by its ligand androgen (Callaway
et al. 1982). Decreasing androgen concentrations during
EE2 treatment could be a reason for this observation; an-
drogen levels were rather high due to AI treatment but
decreased to relatively low levels after EE2 treatment as
has been observed in prostate cancer treatment (Brunton
2006. The other notable finding was that cytosolic staining
of BRCA1 was significantly up-regulated by EE2 whereas
nuclear staining tended to decrease (Table 2). BRCA1 and
BRCA2 are tumor suppressor genes and these mutations
were strongly associated with hereditary breast cancer
(Yoshida and Miki 2004; Duncan et al. 1998). BRCA1 is
responsible for repairing DNA and when normally
expressed it helps repair damaged DNA or destroys cells if
the DNA cannot be repaired. BRCA1 staining was mainly
observed in nuclei but was also present in the cytosol.
BRCA1 nuclear staining was frequently reduced in breast
tumor tissue compared to normal tissue. The protein
stained in the cytosol was considered to be a mutated
form of BRCA1 (Kashima et al. 2000; Tulchin et al. 2013)
and loss of nuclear BRCA1 expression is associated with a
highly proliferative tumor phenotype (Jarvis et al. 1998).
Estrogen treatment upregulates BRCA1 expression but
has no effect on cellular localization (Romagnolo et al.
1998). Our results showed that when EE2 treatment ends
i.e. in the post-EE2 group, tumors became resistant to EE2
and started to grow again as shown by the Ki67 index
which tended to increase after treatment. We were unable
to identify the precise reason for BRCA1 translocation;
however it may be related to tumor re-growth.
One interesting finding was that EE2 activated ER sig-
naling, as we observed in PgR regulation; however, EE2
did not stimulate cell growth. Of the 6 patients in this
study, 5 patients responded indicating that EE2 sup-
pressed tumor growth. ER signaling occurs not only via
the classical ER genomic pathway through the estrogen
responsive element (ERE), but also by cross-talk between
growth factor receptors, the so called non-genomic
pathway, and might involve acquisition of hormone ther-
apy resistance (Johnston 2010). Comparison between pa-
tients suggested the possibility of differences in the
regulation of PgR and AKT/pAKT in the non-responsive
patient (Figure 2). It has been reported that long-term
estrogen depletion involves a possible contribution of
the Akt pathway to the phosphorylation of ER (Fujiki
et al. 2014) in breast cancer cells. We could speculate;
1st that EE2 might act in the same manner as E2; how-
ever, transcriptional circumstances are changed during
long-term hormone treatment; 2nd that EE2 could show
differences in conformation and induce recruitment of
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pathways include not only the direct genomic pathway
but also membrane or non-genomic pathways. Stimula-
tion of another pathway or an imbalance of activation
could affect the response to EE2 and hormone resist-
ance. The results of gene expression profiling show wide
variations between patients and we need more cases and
samples to conclude whether long term estrogen deple-
tion causes activation or inactivation of estrogen recep-
tor signaling (Martin et al. 2005; Martin et al. 2003),
Non-responder might have dysfunction of estrogen-ER
signaling and might be stimulated cell proliferation by
non-genomic pathway.
The biology of estrogen-depleted cells was investigated
by cell culture, which indicated that estrogen depleted
estrogen dependent cells increased ER expression and
became sensitive to estrogen. These cells were able to
grow at lower doses of estrogen (Martin et al. 2005).
Additionally, treatment with estrogen within the normal
range did not increase proliferation but induced apop-
tosis in estrogen-depleted cells (Martin et al. 2005). Re-
cently it was reported that genomic mutation of the ER
itself could occur during long-term hormone therapy
(Jeselsohn et al. 2014). This mutated ER then becomes
hypersensitive to estrogen and is able to grow even with
super low amounts of estrogen, suggesting that this is
one of the possible mechanisms by which these cells de-
velop resistance to hormone therapy. Ellis et al. investi-
gated the effects of different concentrations of EE2, 6
mg or 30 mg per day (Ellis et al. 2009) and reported that
the effect of 6 mg was similar to that obtained with a
dose of 30 mg. Therefore, the lower dosage of 6 mg was
sufficient to examine its function further. In our study,
all 18 patients were administered 6 mg per day and
showed a response rate of 50% and a clinical benefit of
56% (Iwase et al. 2013).Conclusions
EE2 is a truly effective and beneficial agent; however we
need to accumulate further knowledge to understand
how to apply this medicine: its dosage, application and
criteria. Additionally, the mechanism underlying the ef-
fects of EE2 acting through the ER is still not clearly
understood.
In this study, the total number of samples was too
small to analyze and reach a valid conclusion concern-
ing the mechanism of hormone therapy resistance. We
will continue to enter the data from the other patients
in the EE2 trial. In the future, it will be obligatory to
perform large scale gene expression profiling because an
unknown gene or gene family may be involved in
changing critical characteristics. Further investigation
is awaited.Materials and methods
Patients and samples
This EE2 trial was approved by the institutional review
board of Kumamoto University Hospital and registered
to UMIN center (UMIN000002831). This study was
informed to all patients and we obtained consent to
participate in the study and consent to publish. The
criteria for registration have previously been described
in detail (Iwase et al. 2013). Briefly, all patients had
received prior sequential hormone therapies including
chemotherapy. Each patient’s pretreatment history is shown
in Table 3.
A total of 23 tissue samples were obtained from 6
patients; however, 4 pre-treatment samples and one
post-treatment sample were not evaluated in this study
to avoid the complicating effects of chemotherapy.
Therefore, 18 tissues from 6 patients were used in this
study. All patients had been administered EE2 after
long-term treatment with multiple anti-hormone agents.
Tissue samples were collected by core needle biopsy from
metastatic lesions of patients who had undergone EE2
treatment at certain clinical points, as shown in Table 3.
Of the 18 samples, 10 samples were obtained before EE2
treatment, 3 were collected during treatment and 5 were
obtained after treatment. All samples were used for the
immunohistochemical (IHC) study to compare expression
during this time period.
Antibody, immunohistochemical methods and evaluations
A total of 13 different staining procedures were performed
in this study, including immunostaining for 11 breast can-
cer-related genes plus one antibody to detect phosphory-
lated protein and TdT-mediated dUTP nick end labeling
(TUNEL). These 13 targeted proteins or markers are func-
tionally categorized into 6 groups: nuclear receptors (ERα,
PgR, AR); growth factors (Her2, IGF1Rb, TGFβR1); tumor
suppressor genes (BRCA1); cell proliferation (Ki-67,
TUNEL); apoptosis related (Fas); intracellular signal trans-
duction (AKT, pAKT, PI3K). Information on all the anti-
bodies is shown in Table 3.
All formalin-fixed, paraffin-embedded specimens were
cut into 4-μm sections, deparaffinized, heated 3 times
for 5 min each in citrate buffer (pH 7) in a 1,000 W
microwave for antigen retrieval and incubated for 10
min in distilled water containing 3% hydrogen peroxide.
The primary antibody was applied after blocking, and in-
cubated at 4°C overnight. Detection and visualization
was performed by several methods as indicated in
Table 4, according to the manufactures’ protocol. As a
negative control, parallel sections were immunostained
without exposure to primary antibodies. No immunore-
activity was observed in these sections.
This study was reported according to the Reporting
Recommendations for Tumor Marker Prognostic Studies
Table 3 Characteristics of patients and the timing of tissue collection
Patient number/age Previous treatment EE2 response/biopsy site
LHRHa LHRHa LHRHa
1 + Tam + ANA + L TS-1 VNR PTX E EE2 L EE2
10m 12m 3m 12m 21m 3m 4m 14m 5m Responder liver, local
59 ^ ^
B A
2 TS-1 + Responder lymph node
DTX ANA E EC DTX XC L EE2 L EE2
15m 13m 5m 13m 24m 6m 7m 14m 6m
62 ^ ^
B A
3 H + Non-responder local
FEC XT ANA E EE2 FUL PTX
3m 12m 8m 2m 4m 3m
56 ^ ^ ^ ^ ^
B B B A A
E MPA Tam L TS-1 ANA Tor EE2 L Responder skin
4 8m 9m 2m 13m 8m 2m 12m
64 ^ ^ ^ ^
B B D A
AC H L Tor E+H PTX L EE2 FuL Responder local
5 8m 7m 8m 6m 1m 4m 3m 8m
58 ^ ^ ^ ^ ^ ^ ^ ^
B B B B B B D A
L ANA XC TS-1 ANA Tor PTX ANA EE2 Responder local
6 16m 3m 9m 3m 2m 7m 11m 3m 14m–
83 ^ ^
B B
^: the time point when tissue was obtained.
B: before EE2 treatment D: During EE2 treatment; A: After EE2 treatment.
Sample shown in bold letter were used in this study.
Abbreviations: ANA: anastozole; AC: doxorubicine + cyclophosphamide; DTX: docetaxel; E: exemestane; EC: Epirubicine + cydophoshamide; FEC: cydoshsphamide + epirubine+5-FU; FUL: fulvestrant; H: herceptine;











Table 4 List of antibodies and methods of visualization
Antibody Source Dilution Visualization
ER 1D5 (Dako) Mouse monoclonal 1:50 Histofine Simple stain MAX-PO° (Nichirei)
PgR PgR636 (Dako) Mouse monoclonal 1:800 Histofine Simple stain MAX-PO° (Nichirei)
AR NCL-AR-318 (Leica) Mouse monoclonal 1:100 VECTASTAIN Elite ABC (Vector)
Ki67 MIB-1 (Dako) Mouse monoclonal 1:50 I-VIEW DAB universal kit (Roche)
BRCA1 MS110 (Abcam) Mouse monoclonal 1:200 Histofine Simple stain MAX-PO° (Nichirei)
IGF1Rb #3027 (CST) Rabbit polyclonal 1:600 VECTASTAIN Elite ABC (Vector)
TGFβR1 8A11 (Abcam) Mouse monoclonal 1:100 VECTASTAIN Elite ABC (Vector)
Fas C18C12 #4233 (CST) Rabbit monoclonal 1:480 SignalStain° boost (CST)
AKT 11E7 #4685 (CST) Rabbit monoclonal 1:100 SignalStain° boost (CST)
pAKT (Ser473) D9E #4060 (CST) Rabbit monoclonal 1:50 SignalStain° boost (CST)
PI3K p85 M253 (Abcam) mouse monoclonal 1:200 VECTASTAIN Elite ABC (Vector)
Her2 anti-HER2 (4B5) (Roche) Rabbit monoclonal I-VIEW DAB universal kit (Roche)
TUNEL TUNEL Apoptosis Detection Kit (Millipore)
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ing and cytoplasmic staining were independently scored
by HS. The HS represented the product of the staining
intensity (0: negative, 1: weak, 2: moderate and 3: strong)
and the percentage of positive cells (0–100%) for each
sample, with a maximum HS of 300. We counted ap-
proximately 100 cancer cells in five randomly-chosen
microscopic fields. Cytomembrane staining was evalu-
ated according to the recommendation for Her2 staining
(Wolff et al. 2013), with staining categorized into scores
of 0, 1+, 2+ and 3+.Statistical analysis
The nuclear or cytosolic staining of each protein was sta-
tistically analyzed. The Wilcoxon signed-rank test was
used for comparisons between 2 groups and the Kruskal-
Wallis test was used for 3 groups. Membrane staining was
analyzed using Student’s t-test between groups. P values <
0.05 were considered a significant result. All analyses were
performed using JMP software version 10.0.1 for Win-
dows (SAS institute Japan, Tokyo, Japan).Abbreviations
AI: Aromatase inhibitor; AKT: Protein kinase B; AR: Androgen receptor;
BRCA1: Breast cancer susceptibility gene I; E2: 17β-estradiol; EE2: Ethinyl
estradiol; ER: Estrogen receptor; ERE: Estrogen responsive element;
Her2: Human EGFR-related 2; HS: Histo-score; IGF1Rb: Insulin-like growth
factor I receptor beta; pAKT: Phosphorylated AKT; PgR: Progesterone
receptor; PI3K: Phosphoinositide 3-kinase; REMARK: Recommendations for
Tumor Marker Prognostic Studies; SERMs: Selective estrogen receptor
modulators; TGFβR1: Transforming growth factor beta receptor 1;
TUNEL: TdT-mediated dUTP nick end labeling; UMIN: The University Hospital
Medical Information Network.Competing interests
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